Stem Cell Treatment for Crohn’s Disease: When to Consider It Beyond Biologics

In this episode, we explore when stem cell treatment for Crohn’s disease may become an option for patients who no longer respond well to biologic therapies. We also examine what the latest research says, where the evidence stands today, and what patients should know before considering this emerging treatment.

You’ll learn:

• Why biologic therapies stop working for some people with Crohn’s disease
• How mesenchymal stem cells (MSCs) may help reduce inflammation and support tissue repair
• The difference between local stem cell injections and whole-body stem cell transplants
• What happened with the first FDA-approved stem cell therapy for Crohn’s fistulas, and why it was withdrawn from the European market
• What current research shows about umbilical cord-derived stem cells and their potential benefits
• Whether stem cell therapy is considered a biologic and how it differs from traditional biologic drugs
• When doctors may recommend discussing stem cell therapy after standard treatments have failed
• Why realistic expectations and specialist guidance are essential when exploring regenerative medicine for Crohn’s disease

While stem cell treatment for Crohn’s disease continues to show promise, it is not a cure and is best viewed as a supportive option alongside proven medical care. This episode explains who may benefit, what questions to ask your specialist, and how to make informed decisions based on the latest clinical evidence.

Blog Link: Stem Cell Treatment For Crohn’s Disease: When to Consider It Beyond Biologics

Transcript

SPEAKER_00 0:00

Welcome to the Sirena Cell podcast. So imagine finding this uh this miracle drug, right? One that just completely suppresses your debilitating autoimmune disease.

SPEAKER_01 0:10

Right. You finally feel like you've got your life back.

SPEAKER_00 0:12

Exactly. You're making plans, you have all this energy, the pain is finally gone, and then maybe like a year later, your own body secretly builds an army of antibodies to destroy that very drug.

SPEAKER_01 0:24

Which is just it plunges you right back into sickness.

SPEAKER_00 0:26

Yeah. And for thousands of people living with Crohn's disease, this isn't just some nightmare scenario. It's a biological reality. It's this thing known as secondary loss of response. Aaron Powell Yeah.

SPEAKER_01 0:36

It's arguably one of the most um frustrating phenomena in modern medicine because we have this tendency to view our bodies as these static machines, you know?

SPEAKER_00 0:45

Like a car. You just replace the part.

SPEAKER_01 0:47

Right, exactly. You find the broken part, you apply the specific chemical tool, and it runs smoothly again. But the human immune system is just intensely dynamic. It learns.

SPEAKER_00 0:55

It adapts.

SPEAKER_01 0:56

It adapts. And quite often it learns how to outsmart the monkey billion dollar pharmaceuticals we designed to control it.

SPEAKER_00 1:02

Aaron Powell, which brings us to the mission of our deep dive today. We are looking at a curated stack of sources, specifically clinical documentation and protocols from CeronaCell, which is a regenerative medicine center.

SPEAKER_01 1:14

Aaron Powell Yeah, we're really focusing in on stem cell treatment for Crohn's disease today.

SPEAKER_00 1:18

Aaron Powell Right. Because we want to cut through the internet hype and figure out when it actually makes sense to look beyond standard biologic drugs. So we are speaking directly to you, the listener, whether you're managing Crohn's yourself or supporting someone who is.

SPEAKER_01 1:32

Aaron Powell Because there is just a lot of noise out there. The Internet is flooded with wild, unregulated promises about stem cells right now. Trevor Burrus, Jr.

SPEAKER_00 1:42

Oh, absolutely. So we're going to look at how the science actually works, the major historical failures in the field, and how clinics like Serona Cell in Malaysia are creating structured, doctor-led protocols to manage this safely.

SPEAKER_01 1:54

Aaron Powell Yeah, because if you're going to look beyond the standard of care, especially for a complex condition like Crohn's, you really need to understand the mechanism of action. You have to know the risks of mass-produced cells.

SPEAKER_00 2:04

Aaron Powell And why medical supervision is totally non-negotiable. So let's start with the wall that patients hit. The whole reason we're even discussing regenerative medicine is that the standard tools eventually just run out.

SPEAKER_01 2:16

Right. For a couple of decades now, biologic therapy, specifically anti-TNF drugs, have been the absolute gold standard for Crohn's.

SPEAKER_00 2:24

Okay, let's unpack this because we need an analogy here. Why does the body just suddenly stop liking a drug?

SPEAKER_01 2:30

Well, to understand why they fail, you kind of have to understand how they work first. So in a healthy person, inflammation is a localized temporary response to an injury, right? Or an infection. Exactly. But in Crohn's disease, the immune system is just misfiring. It's relentlessly attacking the lining of the digestive tract. So anti-TNF biologics act like highly specialized molecular interceptors.

SPEAKER_00 2:57

Like a bouncer.

SPEAKER_01 2:58

Yeah, like a highly trained bouncer at the door of a club. And his only job is to spot one specific known troublemaker, this inflammatory protein called tumor necrosis factor, and keep him out.

SPEAKER_00 3:08

So the club stays peaceful. But earlier I mentioned that the body builds an army to destroy the drug. Why does the immune system suddenly turn on the bouncer?

SPEAKER_01 3:18

Because fundamentally that bouncer is an outsider. Biologic drugs are large, complex proteins, and they're often derived from living cell lines, sometimes from mice, sometimes synthesized human lines.

SPEAKER_00 3:30

Oh wow, so they're foreign.

SPEAKER_01 3:32

Right. Even though they're doing a helpful job, your immune system is constantly surveilling your blood for anything foreign. And eventually it recognizes the biologic's protein structure as alien.

SPEAKER_00 3:43

It's like it identifies the uniform the bouncer is wearing and just decides, hey, he's actually an invader.

SPEAKER_01 3:47

Precisely. The body's B cells start producing anti-drug antibodies. They just swarm the biologic and neutralize it before it can even attempt to block the inflammation.

SPEAKER_00 3:56

So what does a doctor do then? Just give you more of it?

SPEAKER_01 3:59

They might try that, yeah. Increasing the dose, flooding the system with more of the drug, but the immune system just scales up its antibody production and response. So the inflammation comes roaring back.

SPEAKER_00 4:10

And when that secondary loss of response happens, the medical protocol is usually to pivot to a completely different class of drugs, right? Like you see patients moving to anti-integrin therapies or uh anti-IL 1223 drugs.

SPEAKER_01 4:25

Yeah, those are the common next steps.

SPEAKER_00 4:26

But what do those actually do differently? Are they just different bouncers?

SPEAKER_01 4:30

Basically, yes, but they target entirely different mechanisms. So instead of blocking the inflammation signal itself, anti-integrants act more like a physical roadblock.

SPEAKER_00 4:38

Okay, how so?

SPEAKER_01 4:39

They bind to the surface of white blood cells and physically prevent them from migrating out of the bloodstream and into the gut tissue. And then anti-IL-1223 drugs target different chemical messengers entirely.

SPEAKER_00 4:52

But it sounds like the overarching problem is still there.

SPEAKER_01 4:54

It is. They are all still large foreign proteins targeting a single specific pathway. And the body can and often does eventually build antibodies against those two.

SPEAKER_00 5:04

And as you burn through those options, I mean the physical toll of Crohn's, just compounds. Looking at the clinical data here, we're talking about severe strictures, which is this thick scar tissue that narrows the intestines.

SPEAKER_01 5:15

Yeah, which causes terrible blockages.

SPEAKER_00 5:17

And then there are complex perilanal fistulas, which for anyone unfamiliar, these are incredibly painful abnormal tunnels that the body essentially bores between the inflamed bowel and the skin.

SPEAKER_01 5:30

It's excruciating.

SPEAKER_00 5:31

Yeah.

SPEAKER_01 5:31

And once you hit that stage and the biologics are failing, the conversation almost always shifts to surgery, resecting the bowel.

SPEAKER_00 5:38

For anyone on this medical treadmill, hitting that wall is terrifying. Which forces a completely different approach, right? Because if biological sniper fire taking out one molecule at a time gets thwarted by the body, you need something that communicates more broadly.

SPEAKER_01 5:53

Exactly. And that brings us to stem cells.

SPEAKER_00 5:55

But let me ask a foundational question first, just about the terminology. Are stem cells actually considered biologics?

SPEAKER_01 6:02

Technically, yes. Regulatory agencies like the FDA or the EMA do classify them under the broad umbrella of biologics simply because they are living cells rather than synthesized chemicals.

SPEAKER_00 6:13

Okay.

SPEAKER_01 6:13

But functionally and mechanistically. They operate in a completely different universe than traditional biologic drugs.

SPEAKER_00 6:19

Well, I want to push back a bit or at least clear up a major misconception right away, because when most people hear stem cells for Crohn's, they picture these microscopic construction workers. Trevor Burrus, Jr.

SPEAKER_01 6:31

Right. The drywall analogy.

SPEAKER_00 6:32

Yeah. Like you infuse the cells, they travel to the holes in the intestines, and they just turn into fresh gut tissue to patch up the damage. But wait, so if I get stem cells for Crohn's, they aren't just acting like microscopic construction workers.

SPEAKER_01 6:45

No, not at all. What's fascinating here is that the true mechanism is entirely different. Most of the research for Crohn's focuses on MSEs or mesenchymal stem cells, and they don't replace tissue directly.

SPEAKER_00 6:58

So what are they actually doing if they aren't rebuilding the tissue?

SPEAKER_01 7:01

They are executing what is known as the pericrine effect. So rather than acting as construction workers, they function more like microscopic diplomats assessing a battlefield.

SPEAKER_00 7:10

Diplomats. That's an interesting way to put it.

SPEAKER_01 7:12

Yeah, because when they encounter severe inflammation, they release a massive, complex payload of biological signals. Cytokines, growth factors, specialized proteins all secreted into the surrounding environment at once.

SPEAKER_00 7:26

Oh wow. So going back to our earlier analogy, if a traditional biologic drug is like a sniper, cutting one specific wire to diffuse a bomb, MSCs are more like uploading a localized software update to the immune system.

SPEAKER_01 7:39

That is a highly aggregate way to frame it. Yeah. It reboots the system. It tells the inflammatory cells to just stop recognizing the gut as an enemy.

SPEAKER_00 7:48

It's a dynamic multi-signal response.

SPEAKER_01 7:50

Exactly. The MSEs actively sense the level of inflammation and tailor their release of chemical messengers to calm the aggressive T cells. Right. And that supports local tissue repair.

SPEAKER_00 8:00

Which is why they're heavily researched for treating those stubborn perietal fistulas we mentioned.

SPEAKER_01 8:05

Right, because the MSEs instruct the surrounding damaged tissue to initiate its own healing process.

SPEAKER_00 8:10

And this multi-signal approach seems to have really broad applications. Because the sources briefly touch on ulcerative colitis or UC as well.

SPEAKER_01 8:18

Yes, they do.

SPEAKER_00 8:18

And Crohn's can affect the entire digestive tract in random patches, whereas UC is restricted just to the lining of the colon. But because both are driven by this overactive immune response, that software update from the MSCs could theoretically work for both, right?

SPEAKER_01 8:34

Yes. The underlying mechanism of immune dysregulation is similar enough that this peracrine calming effect is being studied for both conditions.

SPEAKER_00 8:42

Okay, so if we have these brilliant dynamic cells that can reboot the immune system without triggering the antibody hit squads, why isn't this the first-line treatment for everyone?

SPEAKER_01 8:52

That is the big question.

SPEAKER_00 8:53

Yeah. Why are we still relying on the sniper approach at all?

SPEAKER_01 8:57

Because harnessing living cells is infinitely more complicated than synthesizing a chemical. To understand why this isn't a frontline universal treatment, we really have to look at the harsh reality of biological scaling.

SPEAKER_00 9:09

Right, the logistics of it.

SPEAKER_01 9:10

Exactly. And the best cautionary tale of scale in the Crohn's space is the story of a drug called Darvid Strossel, which was known commercially as allofiesel.

SPEAKER_00 9:19

This is a fascinating and honestly somewhat heartbreaking story in the clinical data. Take us back to 2018. What was happening with allofisol?

SPEAKER_01 9:28

So in 2018, the European Union officially approved Darvid Strossol. And this was a massive milestone. It was the first allogenaic, meaning donor-derived stem cell therapy, specifically approved for Crohn's complex pyrinetal fistulus.

SPEAKER_00 9:43

Based on the Adam RECD trial, right?

SPEAKER_01 9:45

Yes, exactly. It was a rigorous, randomized, double-blind, placebo-controlled study. And the results were stellar. The patients receiving the local injections of these stem cells showed significantly higher rates of clinical remission compared to the placebo group.

SPEAKER_00 10:00

It looked like the holy grail. I mean, the regulators gave it the green light, and it seemed like the stem cell era for Crohn's had officially arrived. But here's where it gets really interesting.

SPEAKER_01 10:08

Yeah, the plot twist.

SPEAKER_00 10:09

The product was completely withdrawn from the EU market at the end of 2024. What actually went wrong between that initial triumph and the withdrawal?

SPEAKER_01 10:17

Well, the manufacturer had to run a much larger phase three follow-up trial to confirm the long-term efficacy on a global scale. This was the Adma Meyer CD2 trial. They enrolled 568 patients across Europe, Israel, and North America.

SPEAKER_00 10:33

Okay, and I'm looking at the numbers from that phase three trial right now, and they are shocking. At the 24-week mark, for the patients who received the cutting-edge stem cell therapy, the remission rate was 48.8%. Right. And for the patients who received a simple placebo, the remission rate was 46.3%. You're telling me that after all the hype, the stem cells perform basically like a coin flip compared to doing absolutely nothing.

SPEAKER_01 10:56

Aaron Powell A margin of just 2.5 percentage points. The regulators deem the difference too small to justify it.

SPEAKER_00 11:03

How does a treatment go from a definitive medical breakthrough in a small trial to a statistical rounding error in a massive one?

SPEAKER_01 11:10

That is the million dollar question in regenerative medicine right now.

SPEAKER_00 11:13

Yeah.

SPEAKER_01 11:13

And it all comes down to the fragility of the product itself.

SPEAKER_00 11:15

Because they're living things.

SPEAKER_01 11:17

Exactly. When you run a small trial, you can tightly control the handling of the cells. They are cultured carefully, move short distances, and administered at peak vitality. But when you scale up to a multinational trial with nearly 600 patients, we're mass producing them. You are. Yeah. You're freezing them, shipping them across oceans, storing them in different hospital freezers, sawing them out, and then finally injecting them.

SPEAKER_00 11:40

You're treating living breathing cells the same way you treat a bottle of ibuprofen.

SPEAKER_01 11:45

And living cells just cannot survive that kind of industrial supply chain without consequence. Mass expansion in a laboratory ages the cells. Freezing and thawing stresses them immensely.

SPEAKER_00 11:56

So they just lose their potency.

SPEAKER_01 11:58

By the time those cells were injected into the phase three patients, it's highly likely they had lost a significant portion of their pericrine signaling capability. They were no longer those vibrant diplomats.

SPEAKER_00 12:08

They were just exhausted.

SPEAKER_01 12:09

Exhausted, degraded cells, unable to deliver the necessary software update. So the regulators looked at that tiny 2.5% margin and determined that at a mass commercial scale, the clinical benefit just wasn't there.

SPEAKER_00 12:22

It is worth noting, just for accuracy, that it remains approved and used in Japan, likely due to different regional logistics. But for a patient reading the headline, major stem cell drug pulled from market, it would be so easy to dismiss the entire field as a failure.

SPEAKER_01 12:39

If we connect this to the bigger picture, though, doing so would be misinterpreting the data. The failure of Darvonstrosol doesn't prove that stem cells don't work.

SPEAKER_00 12:48

Right.

SPEAKER_01 12:48

It proves that the industrial mass production model doesn't work for living cells. It proves that this must remain a carefully considered, highly supervised option rather than some mass market miracle cure.

SPEAKER_00 13:00

So given that setback, the specific source of the stem cells and the medical supervision surrounding them become the absolute most critical factors for any patient exploring this route.

SPEAKER_01 13:10

Unquestionably.

SPEAKER_00 13:11

Which brings us to the specific protocols from Saronacell. They are a regenerative medicine center based in Kuala Lumpur, Malaysia.

SPEAKER_01 13:18

Yes, and they support both local and international patients, including a lot of people flying in from Australia and the Middle East.

SPEAKER_00 13:24

And fun fact, from the sources, their name actually comes from a Celtic goddess of health and protection, which perfectly mirrors their whole philosophy of safe, science-led care over those quick fix promises you see online.

SPEAKER_01 13:37

It's a very fitting name, because looking at their documentation, you can see how they've engineered their entire clinical pathway to avoid the exact pitfalls that doomed those mass-produced therapies.

SPEAKER_00 13:49

So let's talk about the specifics of the science. What does Cirenacell actually use? Because Darvaster cell used cells from fat tissue.

SPEAKER_01 13:56

They did. But Cironocel utilizes something different: ethically sourced umbilical cord-drive cells. Specifically early passage WJMSCs from Wharton's jelly.

SPEAKER_00 14:07

Wait, Wharton's jelly? I mean, I've heard of parents paying to bank cord blood when their baby is born, but are you saying clinics are using the actual tissue of the umbilical cord itself?

SPEAKER_01 14:15

Yes, it's a critical distinction. Cord blood is rich in hematopoietic stem cells, which create blood and immune cells, but the Wharton's jelly, which is the actual gelatinous tissue insulating the blood vessels inside the cord, is one of the richest sources of mesenchymal stem cells in the human body.

SPEAKER_00 14:31

Wow, okay. But where do they get it?

SPEAKER_01 14:33

Clinics acquire this tissue from healthy, full-term deliveries entirely with the donor-mother's consent. It causes zero harm to the mother or child. It's literally tissue that would otherwise be discarded as medical waste.

SPEAKER_00 14:47

Okay, but what about the immune system? If I have Crohn's and my immune system is already hypervigilant and attacking my own gut, won't it just instantly attack cells from a donor's umbilical cord?

SPEAKER_01 14:58

Amazingly, no. MSCs derived from Wharton's jelly are considered immune-privileged.

SPEAKER_00 15:04

Meaning what? Exactly.

SPEAKER_01 15:05

They lack the specific surface markers that our immune system uses to identify foreign invaders. Plus, because they are sourced at the moment of birth, these cells are essentially at day zero of their biological clock.

SPEAKER_00 15:18

Oh, that makes sense.

SPEAKER_01 15:19

They are incredibly robust, highly proliferative, and they haven't been exposed to decades of environmental toxins or aging.

SPEAKER_00 15:26

So you completely bypass that supply chain degradation we saw in the Darwin-Strossel trial because you're starting with the most vibrant cells possible and you aren't subjecting them to massive industrial expansion.

SPEAKER_01 15:36

Exactly. But the handling still matters immensely.

SPEAKER_00 15:39

Right, because the documentation heavily emphasizes that Serona cell operates under BSL II laboratory standards, strict CGMP, and ISO 9001 quality systems, which to a patient just sounds like corporate jargon. Why does that matter to a living cell?

SPEAKER_01 15:56

Because CGMP, which stands for current good manufacturing practice, isn't just administrative red tape. For a living cell, it is the difference between life and death.

SPEAKER_00 16:06

It's like having a highly structured medical bridge rather than wandering into the wild west of unregulated medical tourism.

SPEAKER_01 16:12

That's a great way to put it. These standards dictate hyper-precise control over the oxygen levels, the temperature, and the sterility of the environment where the cells are processed.

SPEAKER_00 16:21

Because if they get stressed, they stop working.

SPEAKER_01 16:23

Exactly. If an MSc experiences a sudden temperature shift, it alters his protein expression. It stops producing those beneficial peracrine signals, and might even trigger an inflammatory response itself. The strict standards ensure the cells remain perfectly stable right up until the moment they enter the patient.

SPEAKER_00 16:39

And that level of strict biological control also extends to what they absolutely will not do. Cyrena cell draws very firm boundaries in their clinical protocols. No embryonic stem cells and no experimental pluripotent stem cells.

SPEAKER_01 16:54

Which is an essential safety marker for any patient evaluating a clinic. Pluripotent cells have the theoretical ability to differentiate into any type of tissue in the body. Which sounds cool, but introducing them into a human patient carries a huge risk. If they aren't perfectly guided by the body, they can continue growing uncontrollably and form complex tumors called teratomas.

SPEAKER_00 17:16

Oh wow. Yeah, you definitely don't want that.

SPEAKER_01 17:18

Right. So by strictly limiting their protocols to MSCs, the clinic is utilizing cells programmed exclusively for signaling and repair, dramatically reducing the risk of uncontrolled growth.

SPEAKER_00 17:30

So with the clinic's high safety standards established, we have to look at who actually belongs in their treatment programs.

SPEAKER_01 17:34

Yes. Setting realistic expectations is key.

SPEAKER_00 17:37

So what does this all mean for the actual patient? Who is the ideal candidate for these protocols?

SPEAKER_01 17:42

The ideal candidate is someone who has firmly hit that biologic wall. It's the patient experiencing secondary loss of response, burning through anti-TNF therapies without achieving lasting control.

SPEAKER_00 17:54

Or those with the stubborn perianal fistulas.

SPEAKER_01 17:57

Exactly. Or it's the patient who simply cannot tolerate the severe side effects of traditional biologics.

SPEAKER_00 18:03

Okay, so if you fit that profile and you undergo treatment, whether it's the minimally invasive IV infusions or targeted injections, what does the day-to-day outcome look like? Are you suddenly cured? Do you just ditch your GI specialist?

SPEAKER_01 18:17

Any clinic that tells you to throw away your medication on day one is operating unethically. The protocol at Sorona cell is explicitly positioned as an adjunct therapy.

SPEAKER_00 18:26

Meaning it's a supportive option, not a replacement.

SPEAKER_01 18:29

Exactly. It's a powerful addition to your care, but you don't skip standard monitoring. Crohn's remains a chronic condition. The realistic goals here are promoted fistula healing and a reduced frequency of flares, not a guaranteed magical cure.

SPEAKER_00 18:42

It's about restoring a baseline quality of life. So let's synthesize everything we've unpacked today. We started by looking at biologics powerful interceptors that unfortunately have limits because the body adapts and builds antibodies against them.

SPEAKER_01 18:56

Which necessitates a totally different approach. Stem cells offer this dynamic, multi-signal approach to calming the immune system. But as we saw with the alifizzle story, they require intense medical supervision and ethical cell sourcing.

SPEAKER_00 19:11

Which is exactly what clinics like Serona Cell are pioneering. And honestly, for you, the listener, you now have the vocabulary and the historical context to ask the right questions if you ever need to evaluate these options for yourself or a loved one.

SPEAKER_01 19:24

You aren't just relying on internet hype anymore.

SPEAKER_00 19:26

Exactly.

SPEAKER_01 19:26

And, you know, as we wrap up, I just want to leave you with a final thought to ponder. We have spent decades trying to brute force the immune system into submission, right? Treating it like an enemy combatant.

SPEAKER_00 19:37

Like a sniper targeting a single molecule.

SPEAKER_01 19:40

Exactly. But if those traditional drugs often fail when the body adapts, what if the true future of treating complex autoimmune diseases isn't about finding a better sniper?

SPEAKER_00 19:51

Oh, I like where you're going with this.

SPEAKER_01 19:53

What if it's about using the rich multi-signal language of living stem cells to actually teach the body's immune system how to simply tolerate itself again?

SPEAKER_00 20:03

It completely flips the paradigm. Instead of fighting the body, we're finally learning how to communicate with it. Thank you for joining us on this depth dive.